SG11202103917VA - Methods for targeted insertion of dna in genes - Google Patents
Methods for targeted insertion of dna in genesInfo
- Publication number
- SG11202103917VA SG11202103917VA SG11202103917VA SG11202103917VA SG11202103917VA SG 11202103917V A SG11202103917V A SG 11202103917VA SG 11202103917V A SG11202103917V A SG 11202103917VA SG 11202103917V A SG11202103917V A SG 11202103917VA SG 11202103917V A SG11202103917V A SG 11202103917VA
- Authority
- SG
- Singapore
- Prior art keywords
- genes
- dna
- methods
- targeted insertion
- targeted
- Prior art date
Links
- 238000003780 insertion Methods 0.000 title 1
- 230000037431 insertion Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862746497P | 2018-10-16 | 2018-10-16 | |
US201962830654P | 2019-04-08 | 2019-04-08 | |
US201962864432P | 2019-06-20 | 2019-06-20 | |
PCT/US2019/056083 WO2020081438A1 (fr) | 2018-10-16 | 2019-10-14 | Procédés d'insertion ciblée d'adn dans des gènes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103917VA true SG11202103917VA (en) | 2021-05-28 |
Family
ID=68393107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103917VA SG11202103917VA (en) | 2018-10-16 | 2019-10-14 | Methods for targeted insertion of dna in genes |
Country Status (13)
Country | Link |
---|---|
US (12) | US20200115700A1 (fr) |
EP (1) | EP3867372A1 (fr) |
JP (1) | JP7460643B2 (fr) |
KR (1) | KR20210091167A (fr) |
CN (1) | CN113166754A (fr) |
AU (2) | AU2019360182B2 (fr) |
BR (1) | BR112021007229A2 (fr) |
CA (1) | CA3116553A1 (fr) |
DE (1) | DE112019005166T5 (fr) |
GB (2) | GB2611929B (fr) |
IL (1) | IL282290A (fr) |
SG (1) | SG11202103917VA (fr) |
WO (1) | WO2020081438A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12054754B2 (en) | 2017-11-02 | 2024-08-06 | Arbor Biotechnologies, Inc. | CRISPR-associated transposon systems and components |
KR20210091167A (ko) * | 2018-10-16 | 2021-07-21 | 블루알렐, 엘엘씨 | 유전자에서 dna의 표적화 삽입을 위한 방법 |
TW202027797A (zh) | 2018-10-18 | 2020-08-01 | 美商英特利亞醫療公司 | 用於治療α-1抗胰蛋白酶不足的組成物及方法 |
JP7472121B2 (ja) * | 2018-10-18 | 2024-04-22 | インテリア セラピューティクス,インコーポレーテッド | アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法 |
SG11202103734PA (en) * | 2018-10-18 | 2021-05-28 | Intellia Therapeutics Inc | Compositions and methods for expressing factor ix |
EP3867376A1 (fr) | 2018-10-18 | 2021-08-25 | Intellia Therapeutics, Inc. | Constructions d'acides nucléiques et procédés d'utilisation |
US20230212538A1 (en) * | 2020-03-30 | 2023-07-06 | Blueallele, Llc | Methods for integrating dna into genes with gain-of-function or loss-of-function mutations |
KR20230123460A (ko) * | 2020-09-29 | 2023-08-23 | 뉴엑셀 테라퓨틱스 아이엔씨. | Neurod1 벡터 |
US20240018493A1 (en) * | 2020-11-10 | 2024-01-18 | The Board Of Trustees Of The Leland Stanford Junior University | Knock-in of large dna for long-term high genomic expression |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG48698A1 (en) | 1993-04-21 | 1998-05-18 | Univ Edinburgh | Expression of heterologous genes |
JP2001507577A (ja) | 1996-12-31 | 2001-06-12 | ジョージ エイ ガイタナリス | 哺乳動物の遺伝子に変異を導入するためのベクターおよび方法 |
US7316923B1 (en) * | 1997-09-26 | 2008-01-08 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
CA2474486C (fr) * | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Mutagenese chromosomique ciblee au moyen de nucleases en doigt a zinc |
US20040106566A1 (en) | 2002-05-17 | 2004-06-03 | Shi-Lung Lin | RNA-splicing and processing-directed gene silencing and the relative applications thereof |
US7888121B2 (en) * | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US20140271782A1 (en) | 2013-03-15 | 2014-09-18 | Dermazone Solutions, Inc. | Method for preparing nanolipids with encapsulated alcohol |
GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
EP2425000B1 (fr) | 2009-04-30 | 2019-02-20 | The Trustees Of The University Of Pennsylvania | Compositions pour cibler des cellules des voies respiratoires conductrices comprenant des constructions de virus adéno-associé |
WO2013012729A2 (fr) * | 2011-07-15 | 2013-01-24 | E. I. Du Pont De Nemours And Company | Nouvelles séquences terminatrices végétales |
WO2013075008A1 (fr) | 2011-11-16 | 2013-05-23 | University Of Florida Research Foundation Inc. | Systèmes de vecteur double aav pour une thérapie génique |
EP2825652B1 (fr) | 2012-03-15 | 2018-09-05 | Omeros Corporation | Composition et procédé de diversification de séquences cible |
ES2828663T3 (es) | 2012-04-18 | 2021-05-27 | Univ Leland Stanford Junior | Dirección genética no disruptiva |
JP6559063B2 (ja) | 2012-05-07 | 2019-08-14 | サンガモ セラピューティクス, インコーポレイテッド | 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物 |
UA119135C2 (uk) | 2012-09-07 | 2019-05-10 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб отримання трансгенної рослини |
AU2013355327A1 (en) | 2012-12-05 | 2015-06-11 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of metabolic disorders |
BR112015012375A2 (pt) | 2012-12-06 | 2017-09-26 | Sigma Aldrich Co Llc | modificação e regulação de genoma à base de crispr |
WO2014144155A1 (fr) | 2013-03-15 | 2014-09-18 | Regents Of The University Of Minnesota | Ingénierie de génomes de plantes à l'aide de systèmes crispr/cas |
EP2986709A4 (fr) | 2013-04-16 | 2017-03-15 | University Of Washington Through Its Center For Commercialization | Activation d'une autre voie pour la réparation dirigée par homologie afin de stimuler la correction génétique et le génie génomique |
US9944925B2 (en) | 2013-08-02 | 2018-04-17 | Enevolv, Inc. | Processes and host cells for genome, pathway, and biomolecular engineering |
RU2668819C2 (ru) | 2013-09-04 | 2018-10-02 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Быстрый направленный анализ сельскохозяйственных культур для определения донорной вставки |
AR098283A1 (es) | 2013-11-04 | 2016-05-26 | Dow Agrosciences Llc | Polinucleótido donante universal para reconocimiento de genes |
EP3071695A2 (fr) | 2013-11-18 | 2016-09-28 | Crispr Therapeutics AG | Système crips-cas, matériels et procédés |
KR20160097331A (ko) * | 2013-12-12 | 2016-08-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도 |
EP3114227B1 (fr) | 2014-03-05 | 2021-07-21 | Editas Medicine, Inc. | Méthodes et compositions liées à crispr/cas et destinées à traiter le syndrome de usher et la rétinite pigmentaire |
EP3122880B1 (fr) | 2014-03-26 | 2021-05-05 | Editas Medicine, Inc. | Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose |
EP3126495A1 (fr) | 2014-04-02 | 2017-02-08 | Editas Medicine, Inc. | Méthodes se rapportant à crispr/cas, et compositions pour traiter le glaucome à angle ouvert primaire |
WO2015157070A2 (fr) | 2014-04-09 | 2015-10-15 | Editas Medicine, Inc. | Méthodes et compositions se rapportant à crispr/cas et destinées au traitement de la fibrose kystique |
GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
US20170088819A1 (en) | 2014-05-16 | 2017-03-30 | Vrije Universiteit Brussel | Genetic correction of myotonic dystrophy type 1 |
WO2016033246A1 (fr) | 2014-08-27 | 2016-03-03 | Caribou Biosciences, Inc. | Procédés pour augmenter l'efficacité de l'ingénierie médiée par cas9 |
EP3204513A2 (fr) | 2014-10-09 | 2017-08-16 | Life Technologies Corporation | Oligonucléotides crispr et édition de gènes |
CA2963820A1 (fr) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Procedes pour ameliorer l'edition genomique mediee par crispr/cas |
KR102350405B1 (ko) | 2014-12-16 | 2022-01-11 | 다니스코 유에스 인크. | 진균 게놈 변형 시스템 및 사용 방법 |
WO2016109840A2 (fr) * | 2014-12-31 | 2016-07-07 | Synthetic Genomics, Inc. | Compositions et procédés pour une efficacité élevée de l'édition du génome in vivo |
EP3274454B1 (fr) | 2015-03-25 | 2021-08-25 | Editas Medicine, Inc. | Procédés, compositions et constituants liés à crispr/cas |
WO2016154579A2 (fr) | 2015-03-26 | 2016-09-29 | Editas Medicine, Inc. | Conversion génique via crispr/cas |
AU2016244033A1 (en) | 2015-04-01 | 2017-10-19 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating Duchenne Muscular Dystrophy and Becker Muscular Dystrophy |
US11180793B2 (en) | 2015-04-24 | 2021-11-23 | Editas Medicine, Inc. | Evaluation of Cas9 molecule/guide RNA molecule complexes |
JP6851319B2 (ja) | 2015-04-27 | 2021-03-31 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系 |
WO2016183236A1 (fr) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Procédés liés à crispr/cas et compositions pour traiter une infection par le vih et le sida |
CA2986310A1 (fr) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Systemes crispr/cas9 optimises et procedes d'edition de genes dans des cellules souches |
EP3307887A1 (fr) | 2015-06-09 | 2018-04-18 | Editas Medicine, Inc. | Procédés liés à crispr/cas et compositions d'amélioration de la transplantation |
US11555207B2 (en) | 2015-06-17 | 2023-01-17 | The Uab Research Foundation | CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
KR102691636B1 (ko) | 2015-08-31 | 2024-08-02 | 애질런트 테크놀로지스, 인크. | 상동 재조합에 의한 crispr/cas-기반 게놈 편집을 위한 화합물 및 방법 |
WO2017048995A1 (fr) | 2015-09-15 | 2017-03-23 | Mirimus, Inc. | Systèmes de crispr/cas9 et d'arni inductibles et procédés d'utilisation |
EP3786294A1 (fr) | 2015-09-24 | 2021-03-03 | Editas Medicine, Inc. | Utilisation d'exonucléases pour améliorer l'édition de génome à médiation par crispr/cas |
DK3350327T3 (en) | 2015-10-23 | 2019-01-21 | Caribou Biosciences Inc | CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID |
US10240145B2 (en) | 2015-11-25 | 2019-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer |
WO2017155408A1 (fr) | 2016-03-11 | 2017-09-14 | Erasmus University Medical Center Rotterdam | Outil d'édition génomique crispr-cas9 amélioré |
WO2017155407A1 (fr) | 2016-03-11 | 2017-09-14 | Wageningen Universiteit | Outil d'édition génique crispr-cpf1 amélioré |
EP3443086B1 (fr) | 2016-04-13 | 2021-11-24 | Editas Medicine, Inc. | Systèmes d'édition de gènes de molécules de fusion cas9 et leurs procédés d'utilisation |
JP7075597B2 (ja) | 2016-05-05 | 2022-05-26 | デューク ユニバーシティ | デュシェンヌ型筋ジストロフィーを治療するためのcrispr/cas関連の方法および組成物 |
EP3464587B1 (fr) | 2016-05-27 | 2020-12-16 | Life Technologies Corporation | Compositions et méthodes pour améliorer la recombinaison homologue |
EP3472321A2 (fr) | 2016-06-17 | 2019-04-24 | Genesis Technologies Limited | Système crips-cas, matériels et procédés |
MX2019000251A (es) | 2016-07-05 | 2019-10-09 | Univ Johns Hopkins | Composiciones y metodos que comprenden mejoras de los arn guias de crispr usando el promotor h1. |
EP3481434A4 (fr) | 2016-07-05 | 2020-06-24 | The Johns Hopkins University | Compositions à base de crispr/cas9 et méthodes de traitement de dégénérescences de la rétine |
JP6829761B2 (ja) | 2016-09-29 | 2021-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 遺伝子編集モジュールおよび遺伝子送達アプローチを解析および最適化するための方法 |
JP7215716B2 (ja) * | 2017-01-13 | 2023-01-31 | 学校法人自治医科大学 | 肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのaavベクター |
WO2018152325A1 (fr) | 2017-02-15 | 2018-08-23 | Bluebird Bio, Inc. | Modèles de réparation de donneur pour l'édition de génome multiplex |
US20180362590A1 (en) | 2017-04-14 | 2018-12-20 | Synthetic Genomics, Inc. | Polypeptides with type v crispr activity and uses thereof |
US11773409B2 (en) | 2017-04-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors |
WO2018197020A1 (fr) | 2017-04-27 | 2018-11-01 | Novozymes A/S | Édition de génome par crispr-cas9 à l'aide d'oligonucléotides donneurs courts |
WO2019005851A1 (fr) | 2017-06-26 | 2019-01-03 | Arizona Board Of Regents On Behalf Of Arizona State University | Plateforme universelle permettant d'améliorer l'édition de gènes à base de crispr pour des thérapies in vivo |
US20200231974A1 (en) * | 2017-07-18 | 2020-07-23 | Genovie Ab | A two-component vector library system for rapid assembly and diversification of full-length t-cell receptor open reading frames |
KR20200033259A (ko) | 2017-07-31 | 2020-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물 |
US20190032156A1 (en) | 2017-07-31 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
EP3707155A2 (fr) | 2017-11-09 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | Systèmes crispr/cas pour le traitement de dmd |
AU2018378479A1 (en) | 2017-12-05 | 2020-06-18 | Vertex Pharmaceuticals Incorporated | CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof |
EP3723813A4 (fr) | 2017-12-15 | 2021-10-06 | Regents of the University of Minnesota | Édition génomique à médiation par crispr avec des vecteurs |
KR20200119239A (ko) | 2018-02-08 | 2020-10-19 | 지머젠 인코포레이티드 | 코리네박테리움에서 crispr을 사용하는 게놈 편집 |
CN118345049A (zh) | 2018-03-13 | 2024-07-16 | 明尼苏达大学董事会 | 使用Cas9碱基编辑器的淋巴造血改造 |
CA3092088A1 (fr) | 2018-03-15 | 2019-09-19 | Igtx, Llc | Vecteurs d'adn synthetiques et procedes d'utilisation |
JP7334178B2 (ja) | 2018-03-19 | 2023-08-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | CRISPR/Cas系を使用した動物での転写モジュレーション |
CN112469823A (zh) | 2018-04-27 | 2021-03-09 | 西雅图儿童医院d/b/a西雅图儿童研究所 | 布鲁顿氏酪氨酸激酶的基于talen和基于crispr/cas的基因编辑 |
US11827877B2 (en) * | 2018-06-28 | 2023-11-28 | Crispr Therapeutics Ag | Compositions and methods for genomic editing by insertion of donor polynucleotides |
KR20210091167A (ko) * | 2018-10-16 | 2021-07-21 | 블루알렐, 엘엘씨 | 유전자에서 dna의 표적화 삽입을 위한 방법 |
EP3867376A1 (fr) | 2018-10-18 | 2021-08-25 | Intellia Therapeutics, Inc. | Constructions d'acides nucléiques et procédés d'utilisation |
JP7472121B2 (ja) * | 2018-10-18 | 2024-04-22 | インテリア セラピューティクス,インコーポレーテッド | アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法 |
TW202027797A (zh) | 2018-10-18 | 2020-08-01 | 美商英特利亞醫療公司 | 用於治療α-1抗胰蛋白酶不足的組成物及方法 |
SG11202103734PA (en) | 2018-10-18 | 2021-05-28 | Intellia Therapeutics Inc | Compositions and methods for expressing factor ix |
-
2019
- 2019-10-14 KR KR1020217014640A patent/KR20210091167A/ko unknown
- 2019-10-14 CA CA3116553A patent/CA3116553A1/fr active Pending
- 2019-10-14 EP EP19795751.7A patent/EP3867372A1/fr active Pending
- 2019-10-14 DE DE112019005166.0T patent/DE112019005166T5/de active Pending
- 2019-10-14 GB GB2300487.2A patent/GB2611929B/en active Active
- 2019-10-14 GB GB2106906.7A patent/GB2593353B/en active Active
- 2019-10-14 US US16/601,144 patent/US20200115700A1/en not_active Abandoned
- 2019-10-14 CN CN201980079879.4A patent/CN113166754A/zh active Pending
- 2019-10-14 JP JP2021546192A patent/JP7460643B2/ja active Active
- 2019-10-14 WO PCT/US2019/056083 patent/WO2020081438A1/fr unknown
- 2019-10-14 AU AU2019360182A patent/AU2019360182B2/en active Active
- 2019-10-14 BR BR112021007229-2A patent/BR112021007229A2/pt unknown
- 2019-10-14 SG SG11202103917VA patent/SG11202103917VA/en unknown
-
2020
- 2020-02-25 US US16/800,444 patent/US11091756B2/en active Active
-
2021
- 2021-04-13 IL IL282290A patent/IL282290A/en unknown
- 2021-07-02 US US17/366,290 patent/US11254930B2/en active Active
-
2022
- 2022-02-01 US US17/590,613 patent/US11365407B2/en active Active
- 2022-06-01 US US17/830,011 patent/US12054706B2/en active Active
-
2023
- 2023-05-09 AU AU2023202878A patent/AU2023202878A1/en active Pending
- 2023-12-01 US US18/526,713 patent/US20240141317A1/en active Pending
- 2023-12-01 US US18/526,772 patent/US20240141320A1/en active Pending
- 2023-12-01 US US18/526,826 patent/US20240141323A1/en active Pending
- 2023-12-01 US US18/526,808 patent/US20240141322A1/en active Pending
- 2023-12-01 US US18/526,758 patent/US20240141319A1/en active Pending
- 2023-12-01 US US18/526,745 patent/US11993770B2/en active Active
- 2023-12-01 US US18/526,794 patent/US20240141321A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2593353B (en) | Methods for targeted insertion of DNA in genes | |
IL283585B1 (en) | Methods and preparations for targeted genetic modification using paired guide RNA | |
IL288263A (en) | CRISPR DNA/RNA hybrid polynucleotides and methods for using them | |
IL265953A (en) | Gene insertion is targeted for improved immune cell therapy | |
IL259788A (en) | Adapted nucleic acid sequences, preparations containing them and methods for determining duplex sequence using them | |
IL256905A (en) | Methods for Amplifying Nucleic Acid Sequences | |
EP3245220C0 (fr) | Procédés et compositions destinés au transfert de gènes ciblé | |
EP3339437A4 (fr) | Procédé d'insertion spécifique de site d'un adn étranger dans le génome d'une cellule animale et cellule ainsi obtenue | |
SG11202106810UA (en) | Methods for targeted complementary dna enrichment | |
HK1257658A1 (zh) | Sirna及其在抑制nrarp基因表達的方法和組合物中的用途 | |
HUE061474T2 (hu) | Nukleinsav-szekvenálási eljárás |